

902 KAR 2:020

Reportable disease surveillance

Draft

Proposed Changes to HAI/AR Reporting in Kentucky - 1

- **Section 3. Submission of Specimens to the Kentucky Department for Public Health Division of Laboratory Services.**
 - (5) A medical or national reference laboratory shall submit pure isolates or, if not available, the direct specimen from the following diseases to the Division of Laboratory Services.
 - (d) *Candida auris*
 - (e) Carbapenem-resistant *Acinetobacter*
 - (f) Carbapenem-resistant *Enterobacteriaceae*
 - (g) Carbapenem-resistant *Pseudomonas*
 - (w) Vancomycin-intermediate *Staphylococcus aureus*
 - (x) Vancomycin-resistant *Staphylococcus aureus*

Proposed Changes to HAI/AR Reporting in Kentucky - 2

- **Section 10. Multi-Drug Resistant Organisms and Other Organisms Requiring Routine Notification by Electronic Laboratory Reporting.**
 - (a) **Clostridioides (formerly Clostridium) difficile**
 - (b) **Enterobacteriaceae species resistant to ceftazidime, ceftriaxone, or cefotaxime**
 - (c) **Methicillin-resistant Staphylococcus aureus (MRSA)**
 - (d) **Vancomycin-resistant Enterococcus species (VRE)**

Proposed Changes to HAI/AR Reporting in Kentucky - 3

- **Section 11. Multi-Drug Resistant Organisms and Other Organisms Requiring Priority Reporting by EPID 250... Notification of the following diseases shall be considered priority.**
 - **(1) Candida auris**
 - **(2) Carbapenem-resistant – Acinetobacter**
 - **(3) Carbapenem-resistant – Enterobacteriaceae**
 - **(4) Carbapenem-resistant – Pseudomonas**
 - **(5) Vancomycin-intermediate Staphylococcus aureus**
 - **(6) Vancomycin-resistant Staphylococcus aureus**

Proposed Changes to HAI/AR Reporting in Kentucky - 4

- **Section 13. Laboratory Surveillance.**
 - **(3) Upon request by the Kentucky Department for Public Health, a health facility laboratory or a medical laboratory shall report the number of clinical isolates and information regarding the antimicrobial resistance patterns of the clinical isolates at intervals no less frequently than three months for the following:**
 - (a) *Acinetobacter baumannii* complex
 - (b) *Enterobacter cloacae* complex
 - (c) *Enterococcus* species
 - (d) *Escherichia coli*
 - (e) *Klebsiella oxytoca*
 - (f) *Klebsiella pneumonia*
 - (g) *Pseudomonas aeruginosa*
 - (h) *Staphylococcus aureus*

Proposed Changes to HAI/AR Reporting in Kentucky - 5

- **Section 15. Antimicrobial Use Reporting.**

- (1) A short-term acute-care hospital in Kentucky that participates in the Centers for Medicare and Medicaid Services (CMS) reporting programs shall report data on facility-wide inpatient antimicrobial use...Critical access hospitals are exempt.
- (6) Total DOTs are to be submitted for each of the following antimicrobials:

(a) Azithromycin	(f) Clindamycin	(k) Linezolid
(b) Cefepime	(g) Daptomycin	(l) Meropenem
(c) Ceftazidime	(h) Ertapenem	(m) Moxifloxacin
(d) Ceftriaxone	(i) Imipenem	(n) Piperacillin-tazobactam
(e) Ciprofloxacin	(j) Levofloxacin	(o) Vancomycin

- (9) Hospitals that report antimicrobial use data to the NHSN AUR Module will meet this reporting requirement through NHSN reporting.